NL-OMON42791已完成不适用
Immunological monitoring and assessment of biomarkers predictive of clinical response to first-line treatment with bosutinib or imatinib in chronic phase chronic myeloid leukemia - Biomarker substudy for Bfore protocol
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 5
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •1. Molecular diagnosis of CP CML of <= 6 months (from initial diagnosis).
- •Diagnosis of CP CML with molecular confirmation by detection of BCR-ABL rearrangement at screening (cytogenetic assessment for Philadelphia chromosome is not required for enrollment); diagnosis of CP CML will be defined as all of the following:
- •a) <15% blasts in peripheral blood and bone marrow;
- •b) <30% blasts plus promyelocytes in peripheral blood and bone marrow;
- •c) <20% basophils in peripheral blood;
- •d) >=100 x 109/L platelets (>=100,000/mm3);
- •e) No evidence of extramedullary disease except hepatosplenomegaly; AND
- •f) No prior diagnosis of AP or BP-CML.
- •Philadelphia chromosome status will be identified at screening. Both Ph+ and Ph- patients may be included.
- •2. Adequate hepatic and renal function defined as:
- •AST/ALT <=2.5 x upper limit of normal (ULN) or <=5 x ULN if attributable to liver involvement of leukemia.
- •Total bilirubin <=2.0 x ULN (unless associated with Gilbert*s syndrome).
- •Creatinine <=1.5 x ULN.
- •3. Able to take oral tablets.
- •4. ECOG performance status of 0 or 1.
- •5. Age >=18 years.
- •6. Negative serum pregnancy test within 2 weeks of the first dose of study drug if the patient is a woman of childbearing potential. A woman of childbearing potential is defined as a woman who is biologically capable of becoming pregnant. This includes women who are using contraceptives or whose sexual partners are either sterile or using contraceptives. Patients and patient's partners of childbearing potential (physically able to have children) and who are sexually active, must agree to use birth control consistently and correctly during the study and for at least 28 days after they have stopped taking the study drug.
- •7. Ability to provide written informed consent prior to any study related screening procedures being performed.
排除标准
- •1. Any prior medical treatment for CML, including TKIs, with the exception of hydroxyurea and/or anagrelide treatment.
- •2. Any past or current CNS involvement, including leptomeningeal leukemia.
- •3. Hypersensitivity to the active substance or to any of the following excipients: microcrystalline cellulose (E460), croscarmellose sodium (E468), poloxamer 188, povidone (E1201), magnesium stearate (E470b), polyvinyl alcohol, titanium dioxide (E171), macrogol 3350, Talc (E553b), iron oxide red (E172).
- •4. Extramedullary disease only.
- •5. Major surgery or radiotherapy within 14 days of randomization.
- •6. Concomitant use of or need for medications known to prolong the QT interval.
- •7. History of clinically significant or uncontrolled cardiac disease
- •8. Known seropositivity to human immunodeficiency virus (HIV), current acute or chronic hepatitis B (hepatitis B surface-antigen positive), hepatitis C or evidence of decompensated liver disease or cirrhosis.
- •9. Recent or ongoing clinically significant GI disorder, e.g. Crohn*s Disease, Ulcerative Colitis, or prior total or partial gastrectomy.
- •10. History of another malignancy within 5 years with the exception of basal cell carcinoma or cervical carcinoma in situ or stage 1 or 2 cancer that is considered adequately treated and currently in complete remission for at least l2 months.
- •11. Uncontrolled hypomagnesemia or uncorrected hypokalemia due to potential effects on the QT interval.
- •12. Current, or recent (within 6 months), participation in other clinical trials.
- •13. Women who are pregnant, planning to become pregnant during the study or are breastfeeding a child, or men who are planning to father a child during the study.
研究者
相似试验
尚未招募
不适用
se of certain Immunological Markers in blood to detect infection in Neonates.CTRI/2012/05/002651BECTION DICKINSON AND COMPANY100
尚未招募
Unknown
Biomarker Screening for Immunotherapy Response Evaluation using Microneedle Patch in Patients with Allergic RhinitisDiseases of the respiratory systemKCT0008534Yonsei University Health System, Severance Hospital30
尚未招募
不适用
Discovery of biomarkers for immune-mediated liver disease.autoimmune hepatitis, drug-induced liver injury, non-alcoholic fatty liver disease and non-alcoholic steatohepatitisNL-OMON24228Investigator initiated study, funded by the Vrije Universiteit, University Medical Center
尚未招募
不适用
Discovery of non-invasive biomarkers for immune-mediated liver diseases; AIH, DILI, NAFL and NASH.autoimmune hepatitisNL-OMON43305Vrije Universiteit Medisch Centrum100
招募中
不适用
Detection of markers for immune pathophysiology and analysis of their prognostic value in patients with chronic thrombocytopenia without an increase in the number of bone marrow megakaryocytes: a prospective observation study.Pancytopenia, thrombocytopeniaJPRN-UMIN000002729Cellular Transplantation Biology, Kanazawa University Graduate School of Medical Science.50